Patient-Centered Care for the Older Adult With Hematologic Malignancy

Overview

This research study is evaluating if co-management by a geriatrician embedded in the oncology clinic can improve outcomes for frail older adults with blood cancers. A rigorous pre-entry frailty assessment by a trained research assistant will be followed by randomization to geriatrician co-management versus usual care for patients found to be frail or pre-frail.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 1, 2018

Detailed Description

Older adults have unique health concerns, and in particular, older adults with blood cancers may have different disease and other health related issues than younger adults with similar diagnoses. One aspect of aging which can make older adults more vulnerable is frailty. Frailty is a general term that describes a decline in multiple areas of health, including the loss of energy, physical ability, and mental ability. Frailty can make it difficult for patients with cancer to respond to treatment and more likely to have side effects. On the other hand, many older patients are not frail despite advanced age. This study is being done to determine if co-management by a geriatrician of older adults who are found to be frail through a detailed baseline assessment can improve outcomes.

Interventions

  • Other: Baseline Geriatric Screening/Assessment
    • All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
  • Other: Geriatrician Co-Management
    • A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.

Arms, Groups and Cohorts

  • Other: Usual Care
    • Frail/pre-frail hematologic oncology patients receive usual care
  • Active Comparator: Geriatrician Co-Management
    • Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician

Clinical Trial Outcome Measures

Primary Measures

  • Overall Survival
    • Time Frame: One year
    • Overall Survival at one year

Participating in This Clinical Trial

Inclusion Criteria

  • All patients aged 75 and older who present for an initial consultation at the Dana-Farber/Brigham and Women's Cancer Center for hematologic malignancy (transplantation consultation excluded). – Assessed to be pre-frail or frail on formal baseline geriatric assessment. Exclusion Criteria:

  • Not willing to participate

Gender Eligibility: All

Minimum Age: 75 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Dana-Farber Cancer Institute
  • Provider of Information About this Clinical Study
    • Principal Investigator: Gregory A. Abel, MD, Principal Investigator – Dana-Farber Cancer Institute
  • Overall Official(s)
    • Gregory A. Abel, MD, MPH, Principal Investigator, Dana Faber Cancer Institute
    • Jane A Driver, MD, MPH, Principal Investigator, Brigham and Women’s Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.